Podcasts about Ophthalmology

Dr. Edmund Tsui is joined by Dr. Shu Feng, author of Ophthalmology's Assessing the Efficacy of Ophthalmic Transfers to an Academic Level 1 Trauma Hospital, to discuss her study of ophthalmic transfers to an academic level 1 trauma center and the accuracy of transferring diagnoses and rate of intervention after transfer. Assessing the Efficacy of Ophthalmic Transfers to an Academic Level 1 Trauma Hospital. Hopkin, Blake et al. Ophthalmology, Volume 133, Issue 1, 24 – 30.

Charter Medical Private Hospital (CMPH) Mullingar is pleased to announce on behalf of Alliance Medical the launch of its new state-of-the-art CT scanning service in partnership with Alliance Medical, one of Ireland's leading independent diagnostic providers. The enhanced service, delivered on-site in Mullingar, will provide significantly expanded diagnostic capacity for patients across the Midlands. The investment by Alliance Medical in the delivery of the new CT scanning service further enhances CMPH's role as a key regional healthcare provider, supporting faster diagnosis, earlier intervention, and improved outcomes for both public and private patients. It also serves to strengthen the long-term partnership between CMPG and Alliance Medical and is a clear demonstration of support by Alliance Medical in the development of the hospital's infrastructure, along with the ambitious expansion plans of CMPH. The CT service is fully operational and accepting referrals from GPs, consultants and allied health professionals. It provides access to a comprehensive suite of high-quality imaging services. CMPH patients can now access Neuro CT, Orthopaedic & Musculoskeletal, Vascular CT, CT Angiography, and Oncology CT. Cardiac CT will be added shortly, strengthening CMPH's ability to support rapid diagnosis of cardiovascular conditions. All imaging is carried out on-site by Alliance Medical's specialist radiography team, with reporting completed by RCSI-accredited consultant radiologists, ensuring clinical accuracy and rapid turnaround times. The collaboration with Alliance Medical ensures CMPH can provide a best-in-class diagnostic experience while maintaining seamless integration with its surgical, outpatient and public healthcare services. Peter Burke TD, Minister for Enterprise, Trade & Employment, said: "This investment by Alliance Medical into Charter Medical Private Hospital, Mullingar, is extremely positive for local and regional healthcare. Faster access to diagnostics has a profound impact on patient outcomes, and the expansion of the service here in Mullingar will ease pressure on the wider system. It is encouraging to see continued investment in high-quality services and clinical capacity here in Westmeath. I wish both CMPH and Alliance Medical every success with this important initiative. " Paula Gray, Chief Executive Officer, Charter Medical Private Hospital Mullingar, said: "This development represents a major step forward for patient care in the Midlands. Quick access to accurate diagnostics is critical for early detection, effective treatment and peace of mind. By working closely with Alliance Medical, we can now offer patients the highest standard of imaging locally, without long waiting times or the need to travel. This is an important investment in the health of our community and the future of our hospital." Stephen Sullivan, Alliance Medical Unit Manager, Mullingar: "We have seen a great uptake in referrals in the first few months of the service, and we are very excited to see this grow over the course of the year. To be able to offer patients access to high-quality CT scans without the need to travel long distances is a great benefit for the local area." Charter Medical Private Hospital is a 77-bed acute hospital delivering a broad range of clinical, surgical and diagnostic services to patients across the Midlands. It is part of a wider healthcare network employing over 300 professionals across Dublin and Westmeath. CMPH plays a significant role in supporting the HSE through the National Treatment Purchase Fund (NTPF) and Access to Care (ATC) programmes, delivering thousands of procedures in ENT, Ophthalmology, Urology, Dermatology, and General Surgery and minor procedures The hospital is also home to the only public Minor Injuries Unit in the Midlands, treating approximately 10,000 patients per year. CMPH accepts a wide range of insurance providers, including VHI, Laya Healthcare, Irish Life Health, Garda Medical A...

Drs. Zubair Ansari and Kat Talcott join to discuss the 2026 ophthalmology residency match, especially focusing on the declining match rate for first time applicants and what that means for future applicants and reapplicants. Listeners, as we approach our 500th episode, we will be having a Q&A session featuring questions and thoughts from you! It's your chance to have your voice heard on the podcast.Please record an audio / video of your question and upload it to the linked form (https://forms.gle/nyv3fvCHZJ4XzQe67). We are excited to hear what you have to say!

In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meaningful improvement in vision at one year with Dr. Daniel Palanker, Professor of Ophthalmology and Electrical Engineering, Stanford University.

Send a textAbout Dr. Rishi P. Singh MD,Dr. Rishi P. Singh MD is a staff surgeon, vice president, and chief medical officer at theCleveland Clinic Martin Health and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland, Ohio.He specializes in the treatment of medical and surgical retinal disease such as diabeticretinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh hasauthored more than 250 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is on the board of the American Society of Retina Specialists.Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award and American Society of Retina Specialists Senior Honor Award.

Host Dr. Jay Sridhar welcomes Dr. Sarwar Zahid to unpack a recent American Journal of Ophthalmology perspective essay on the growing segment of hospital-employed ophthalmologists. They examine the appeal of the hospitalist model—shift-based work, reduced administrative burden, and work-life balance—alongside potential drawbacks, including income ceilings, RVU pressure, and burnout. The conversation broadens to declining physician ownership, the challenges of hospital call coverage, and the downstream threat to residency training. The episode finally shifts to whether a focused practice designation (FPD) could help define subspecialty expertise, improve patient care, and give ophthalmologists a stronger seat at the bargaining table. Discussed in this episode: Thomson M, Browning DJ. The Hospital Employed Ophthalmologist: A Growing Segment of the Profession. Am J Ophthalmol. 2026 Jan 18;284:208-215. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

The work of the BONSAI (Brain and Optic Nerve Study with Artificial Intelligence) group will change the way we pratice. So a perfect time, then, to meet Dan Milea, Head of Neuro-ophthalmology at the Rothschild Foundation Hospital in Paris, Head of the Visual Neuroscience Group at the Singapore Eye Research Institute, and a founding member of the BONSAI group.Recorded in his Parisian offices within the iconic L'Espace Niemeyer - the striking headquarters of the French Communist Party - Dermot and John explore how groundbreaking AI and deep learning algorithms, developed by the BONSAI collaborators, could transform the way clinicians navigate some of neuro-ophthalmology's most challenging diagnostic dilemmas.Together, we unpack the questions clinicians face every day:* Does this child with headaches have papilloedema?* Is an elderly patient's optic disc swelling arteritic or non-arteritic AION?* Could this suspected optic neuritis be due to demyelination?Dan also reflects on the striking differences in the incidence of optic neuritis, giant cell arteritis, and idiopathic intracranial hypertension between the Far East and Europe and why, when 50% of neuro-ophthalmological emergencies are misdiagnosed at presentation, the growing global shortage of neuro-ophthalmologists is of grave concern.Bonus ContentSubscribers can dive deeper in our Bonus episode, where we discuss the rising tide of idiopathic intracranial hypertension in the West, the emerging therapeutic role of GLP-1 agonists, and explore three of Dan's most influential papers featured in this month's newsletter.Join us for a fascinating look at how East meets West - and how AI may soon be available to support clinical decision making and improve diagnostic accuracy, for many common neuro-ophthalmic conditions.Eyes on Tomorrow is supported by Topcon Healthcare and Thea UK.Produced by Matt Hill at Rethink Audio. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit eyesontomorrow.substack.com/subscribe

In today's podcast, we visit with Dr. Michael Repka, current president of the American Academy of Ophthalmology. Tune in to hear about AAO leadership efforts including advocacy, from Medicare to medical code values.    Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

Have you longed to integrate your Christian faith into your patient care—on the mission field abroad, in your work in the US, and during your training? Are you not sure how to do this in a caring, ethical, sensitive, and relevant manner? This “working” session will explore the ethical basis for spiritual care and provide you with professional, timely, and proven practical methods to care for the whole person in the clinical setting. https://www.dropbox.com/scl/fi/qpah9kh1lttg6cm1jjop9/Bob-Mason-Ethics-of-Spiritual-Care-revised.pptx?rlkey=0emve2ja8282nv8xc4uinq1hg&st=9033htwx&dl=0

Connect with Dr. Rebenitsch: https://www.linkedin.com/in/luke-rebenitsch-md-74663423/Boost Patients | Convert More Modern Vision Correction & Cataract Leads Into Patients | ⁠⁠https://www.boostpatients.com⁠⁠Boost follows up with your New Patient Inquiries 24/7, within 60 Seconds. Their Patient Concierge team calls, texts, and emails potential patients, following up for months and scheduling new patient consultations directly onto your calendar.

Grab your coffee and join us today for our Coffee Conversations with Scientists episode: The Science Behind Glaucoma. Joel Miesfeld, PhD, Assistant Professor of Ophthalmology & Visual Sciences and Assistant Professor of Cell Biology, Neurobiology, and Anatomy at MCW, will join us to discuss the different types of glaucoma and uncover how the eye's internal cellular networks shape vision development and survival. He will also explore emerging research and the potential for regenerating damaged vision through cutting-edge science.

Guest: Courtney Crawford, MD, FACS Guest: Raj Maturi, MD While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida. Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care. References: Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …

Those who hope to honor God and advance Jesus' Kingdom face powerful opposition from spiritual, physical, and psychological enemies. Successful launching and long term fruitfulness depends on recognizing and, in dependence on the Holy Spirit, waging war against those enemies.

Malvina Eydelman, M.D., CEO of The Collaborative Community on Ophthalmic Innovation (CCOI), joins The Rob & Jai Show, an edition of the OIS podcast, to discuss what innovation in the industry looks like in the next 30 years—and if we're hitting a saturation mark. Plus, a deep dive into Eydelman's career in the FDA, her current role at the CCOI, and a big announcement of her next initiative.  In this episode of the OIS podcast, learn about:  Eydelman's time at the FDA and the many hats she wore The goal and plans of the CCOI The role of AI in digital management and getting more patients into the system Details about Eydelman's next big initiative  RESOURCES:  Dr. Rob Rothman: https://ois.net/robert-rothman-md/  Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/  Dr. Malvina Eydelman: https://ois.net/malvina-eydelman/  

We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.

Five ophthalmology practices agreed to pay nearly $6M over alleged kickbacks and unnecessary testing. Learn the FCA risks every physician group must understand.

This episode covers squint.Written notes can be found at https://zerotofinals.com/paediatrics/neurology/squint/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

Medical missionaries often feel powerful emotional burden from moral injury, and it is a leading cause of departure from the mission field. But we have learned proven methods of preventing and dealing with moral injury. Use God’s powerful methods to protect yourself and your team, and to grow in wisdom and spirit!

Drs. Louie Cai and Ted Leng join to discuss the state of artificial intelligence in ophthalmology as of February 2026.

Meet Abdul Rastagar, Head of Marketing at Lexitas Pharma Services, a CRO specializing in ophthalmology clinical trials. Abdul shares his expertise on pharmaceutical marketing, emphasizing the importance of brand awareness and targeted content for lead generation. He also discusses the crucial role of LinkedIn and website development in client acquisition, highlighting the significance of website accessibility in the digital age.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant announcements and strategic initiatives that are shaping the landscape of drug development and patient care.Starting with a notable investment move, Eli Lilly has announced a $3.5 billion manufacturing facility in Pennsylvania, marking a significant milestone in their "Lilly in America" initiative. This facility is set to focus on injectables and devices, reinforcing Lilly's dedication to expanding its manufacturing capabilities within the United States. These types of investments are increasingly crucial as they aim to enhance supply chain resilience and support the production of complex biologics and innovative therapies—a step that could prove pivotal in maintaining a competitive edge in the global pharmaceutical market.Meanwhile, Regeneron's Eylea franchise is encountering challenges with declining sales, even with the introduction of Eylea HD. This situation highlights the difficulties companies face in maintaining market share amidst fierce competition and evolving treatment paradigms in ophthalmology. It underscores the importance of continuous innovation and effective lifecycle management strategies to sustain product competitiveness in a rapidly changing industry environment.Takeda is also navigating turbulent waters with its ADHD medication Vyvanse facing generic competition. Despite this, Takeda maintains an optimistic outlook for future growth by narrowing the revenue gap between declining Vyvanse sales and contributions from new products. This transition is reflective of a broader industry trend where companies pivot towards novel therapeutics to offset revenue losses from patent expirations, exemplifying strategic adaptation in response to market dynamics.AstraZeneca's ambitious $18.5 billion obesity deal with China's CSPC exemplifies the growing focus on metabolic disorders driven by rising global obesity rates. This partnership not only reinforces AstraZeneca's expansion strategy into China but also highlights the increasing importance of addressing obesity—a major public health challenge with significant healthcare cost implications. The deal marks a strategic push to leverage advanced therapeutic approaches, particularly targeting GLP-1 and GIP receptors with long-acting dual agonists. Additionally, AstraZeneca's further $15 billion pledge for investments in Chinese cell therapies and radiopharmaceuticals is expected to enhance its capabilities in personalized medicine and expand its global presence across key therapeutic areas—a reflection of a broader industry trend towards asset-centric deals prioritizing targeted acquisitions over traditional mergers.Novo Nordisk's ongoing legal challenge against drug pricing provisions in the Inflation Reduction Act (IRA) is gaining momentum, with support from the U.S. Chamber of Commerce urging the Supreme Court to review the case. This legal battle underscores ongoing tensions between pharmaceutical companies and regulatory frameworks aimed at controlling drug prices, reflecting broader debates on healthcare affordability and access—a critical issue that continues to shape policy discussions across the industry.Across the Atlantic, CDMO Vetter's €480 million investment in a new plant in Germany signals robust growth in contract development and manufacturing services. This expansion aligns with increasing demand for outsourcing solutions in biopharmaceutical production, driven by complex manufacturing processes and capacity constraints faced by many biotech firms. Such investments are pivotal as they aim to enhance production capabilities and meet growing demands for innovative biologics.Quince Therapeutics recently experienced a setback with its steroid delivery technology for ataxia-telangiectasia, illustrating the Support the show

Synopsis: Fresh from the JPM 2026 in San Francisco, Alok Tayi welcomes Johan Luthman, Executive Vice President of R&D at Lundbeck, for a sweeping, deeply personal conversation on the future of neuroscience drug development. From his early days as a Swedish clinician-scientist to leading breakthrough Alzheimer's programs and rebuilding Lundbeck's pipeline from the ground up, Johan shares the pivotal moments—and phone calls—that shaped a 30-year career across AstraZeneca, Merck, Serono, and now Denmark's neuroscience powerhouse. The discussion dives into Lundbeck's bold strategic reset: letting biology lead, de-risking early in patients, embracing rare disease and sleep medicine, and making disciplined bets on monoclonal antibodies, migraine prevention, epilepsy, and neuroendocrine disorders. Johan explains how the company shifted capital toward innovation, rebuilt its portfolio through targeted acquisitions, and built one of the most advanced neuroscience pipelines in pharma today. In one of the episode's most powerful moments, Johan opens up about his personal motivation—caring for family members with Alzheimer's and dedicating his career to diseases of the brain. From AI-driven R&D productivity and adaptive trials to Denmark's unique foundation-owned pharma model, this conversation is a masterclass in scientific rigor, decision-making under uncertainty, and keeping patients at the center of everything. Biography: In 1991, Johan Luthman began his career in the pharmaceutical industry in Astra, later AstraZeneca. In 2005, Johan joined Serono as Head of Neuroscience & Immunology Research, and subsequently, in MerckSerono, as Therapy Area Head, Neurology & Immunology. In 2009, he became CEO of biotech start-up GeNeuro. In late 2009, Johan joined Merck as VP & Franchise Integrator for Neuroscience and Ophthalmology. In 2014, he came to Eisai where he was Senior Vice President and Head of Clinical Development. Johan joined Lundbeck as Executive Vice President, R&D in March 2019. Johan is a Swedish national and is trained as a Doctor of Dental Sciences from the Karolinska Institute, Sweden. He also holds a PhD in Neurobiology and Histology as well as an Associate Professor title from the Karolinska Institute, Sweden. Johan is a Member of the Board of Directors of Brain+.

In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Retina Division, Byers Eye Institute.

When Jesus began His Church, He did not intend for us to live out our calling in isolation from our fellow believers. He prayed that we would, as the Church, be united as one body. The Apostle Paul also reminded the believers in Corinth that they as part of the body of Christ, indeed functioned like a human body, with many necessary and integral parts, fit together by God Himself for the edification of the saints and the glory of God. This week we continue our conversation with Pastor Chris Legg of South Spring Baptist Church in Tyler, Texas about how he creatively and practically integrates apologetics into his ministry and how each one of us is an apologist, whether we are professionally trained in the field of apologetics or not. Also, Daniel shares his recent terrifying experience in the Grand Canyon. You don't want to miss this episode! Pastor Chris Legg, LPC, and his wife Ginger have been living out the parable of God's love for His people since 1993 and have been blessed with five great kids. He is the Lead Pastor at South Spring Baptist Church in Tyler, TX (https://www.southspring.org ) and is also the founding owner and clinical director of Alethia Family Counseling Center( https://www.alethiacounseling.com ), which offers training, counseling, speaking and business consulting in several locations in Texas.   He and his son Mark are the authors of the book Sex and Marriage, which is intended torestore the power God intended in our marriages.Learn more about SSBC at  www.southspring.org More about Alethia at https://www.alethiacounseling.comContact Chris, read any of his articles, and look for other resources at hiswebsite at https://www.chrismlegg.com and at https://chrismlegg.substack.com/. Resources from Watchman Fellowship: Apologetics Profile podcast interview with Robert Bowman, Jr., about different approaches to Christian apologetics. Atheism Profile by Robert Bowman Jr.: www.watchman.org/profiles/pdf/atheismprofile.pdf Word Faith Movement Profile by Robert Bowman Jr.: www.watchman.org/profiles/pdf/wordfaithprofile.pdfFaith Has Its Reasons: Integrative Approaches to Defending the Christian Faith, by Kenneth Boa and Robert Bowman Jr. (https://amzn.to/2YKeecD)Fast Facts on Apologetics.FREE: We are also offering a subscription to our 4-page bimonthly Profiles here: www.watchman.org/Free.The complete Profile Notebook (Digital Edition, PDF, approx. 700-pages): www.watchman.org/DigitalNotebookSUPPORT: Help us create more content like this. Make a tax-deductible donation here: www.watchman.org/give.Apologetics Profile is a ministry of Watchman Fellowship For more information, visit www.watchman.org © 2026 Watchman Fellowship, Inc.

In the second episode of this two-part series, Drs. Justin Abbatemarco, Valérie Biousse, and Nancy J. Newman discuss the risk of non-arteritic ischemic optic neuropathy and how to counsel patients around GLP-1 medications.  Show transcript:  Dr. Justin Abbatemarco: Hello and welcome back. This is Justin Abbatemarco again with Valarie Biousse and Nancy Newman talking about non-arteritic ischemic optic neuropathy. I think the other major point that we had a discussion in the podcast was around the GLP-1 medications, which you mentioned have been truly life-changing for diabetes management and obesity. Can we talk about the risk of non-arteritic ischemic optic neuropathy and how you're counseling patients around this class of medications? Dr. Nancy J. Newman:  Absolutely. This is probably one of the most difficult things we are dealing with because it is something that is in process and progress right now. We don't have all the information yet, but it would appear that there is likely a small association of about slightly less than two times risk in patients who are taking these medications of having NAION with a resultant still very, very small overall risk. And it is not necessarily causal. This has prompted the European Medicines Agency to say that these patients should have their GLP-1 RAs stopped if they have NAION. Our own FDA and certainly the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have not taken that step, but have suggested that this be shared decision-making, not only with the person who makes this diagnosis of an NAION in the patient, but with their primary care doctor or the provider who has felt that a GLP-1 receptor agonist is important for this patient's treatment and health. Dr. Justin Abbatemarco: More to come. We're going to have you back to have discussions as we learn more and better understand the disease and how we help our patients with both their diagnosis and treatment. Thank you so much for your time. 

Dr. Sophie Bakri is the Chair of the Department of Ophthalmology at Mayo Clinic. She joins us today to share take aways from the recent annual meeting of the American Academy of Ophthalmology.  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

Apologetics might sometimes seem like an off-putting, snobbishly academic endeavor for those among us who are more prone to delight in arguing with nonbelievers. But what might apologetics done properly look like? And what does practical, everyday apologetics look like for believers of all backgrounds and life experiences? In 1 Peter 3:15, we are all called to "give a defense for the hope that is in us, with gentleness and reverence." In that spirit, we as Christians are all apologists. Apologetics is then relevant to our faith, to the church, and to the wider unbelieving culture. This week and next on Apologetics Profile, we'll be chatting with lead pastor of South Spring Baptist Church in Tyler, Texas Chris Legg about these very issues. Pastor Chris will share with us what everyday apologetics looks like in practice in their church, from Sunday mornings and Wednesday nights, to daily life in general. Pastor Chris Legg, LPC, and his wife Ginger have been living out the parable of God's love for His people since 1993 and have been blessed with five great kids. He is the Lead Pastor at South Spring Baptist Church in Tyler, TX (https://www.southspring.org ) and is also the founding owner and clinical director of Alethia Family Counseling Center( https://www.alethiacounseling.com ), which offers training, counseling, speaking and business consulting in several locations in Texas.   He and his son Mark are the authors of the book Sex and Marriage, which is intended torestore the power God intended in our marriages.Learn more about SSBC at  www.southspring.org More about Alethia at https://www.alethiacounseling.comContact Chris, read any of his articles, and look for other resources at hiswebsite at https://www.chrismlegg.com and at https://chrismlegg.substack.com/. Resources from Watchman Fellowship: Apologetics Profile podcast interview with Robert Bowman, Jr., about different approaches to Christian apologetics. Atheism Profile by Robert Bowman Jr.: www.watchman.org/profiles/pdf/atheismprofile.pdf Word Faith Movement Profile by Robert Bowman Jr.: www.watchman.org/profiles/pdf/wordfaithprofile.pdfFaith Has Its Reasons: Integrative Approaches to Defending the Christian Faith, by Kenneth Boa and Robert Bowman Jr. (https://amzn.to/2YKeecD)Fast Facts on Apologetics.FREE: We are also offering a subscription to our 4-page bimonthly Profiles here: www.watchman.org/Free.The complete Profile Notebook (Digital Edition, PDF, approx. 700-pages): www.watchman.org/DigitalNotebookSUPPORT: Help us create more content like this. Make a tax-deductible donation here: www.watchman.org/give.Apologetics Profile is a ministry of Watchman Fellowship For more information, visit www.watchman.org © 2026 Watchman Fellowship, Inc.

Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial." Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press. Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Interview with Kara M. Cavuoto, MD, author of Language Accessibility at Select Academic Ophthalmology Centers Across US Metropolitan Areas. Hosted by Neil Bressler, MD. Related Content: Language Accessibility at Select Academic Ophthalmology Centers Across US Metropolitan Areas  

In this episode of Blind Spot, Zale discusses the controversial topic of bilateral cataract surgery with Dr. Steve Arshinoff, a leading expert in the field. They explore the historical context, current debates, and the potential benefits and risks associated with performing cataract surgery on both eyes simultaneously. Dr. Arshinoff shares insights from his extensive research and experience, addressing common concerns such as infection risks and refractive surprises, and highlights the importance of evidence-based practice in ophthalmology.This episode is sponsored by Thea Pharma Canada - https://www.theapharma.caBecome a supporter of this podcast: https://www.spreaker.com/podcast/blind-spot-the-eye-doctor-s-podcast--5819306/support.

We discuss a study that showed that an artificial intelligence powered system can detect clinically significant fluid as well as experienced observers using the Notal Home OCT with Dr. Ted Leng, Professor of Ophthalmology, Byers Eye Institute, Stanford University.

Dr. Natalia Vergara is an Assistant Professor of Ophthalmology at the Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine on the Anschutz Medical Campus. Natalia uses stem cells to understand how the retina forms during development and how it degenerates during disease with the goal of developing therapies to help patients who suffer from vision loss. For her research, Natalia uses a type of stem cells called induced pluripotent stem cells which can be reprogrammed so they can form any type of cell in the body. With these cells, they can make human retina tissue using any individual's cells in a petri dish in the lab to better understand diseases, test treatments, and potentially prepare retinas for transplant. In her free time, Natalia loves hanging out, cooking, and enjoying food with friends and family, including her husband and two young kids. Natalia is also an avid traveler, and she delights in the thrill of discovery that comes along with exploring new places. Natalia received her B.S. in biochemistry from the National University of the Litoral in Argentina. She worked as an instructor and research intern at the National University of Entre Ríos for about three years before beginning graduate school. Natalia was awarded her PhD in retinal regenerative biology from Miami University in Ohio. Afterwards, she conducted postdoctoral research at the Wilmer Eye Institute of Johns Hopkins School of Medicine. She served as a Research Associate Faculty member at Johns Hopkins School of Medicine for about two years before joining the faculty at the University of Colorado. Natalia has received awards for research and for mentoring, including the Ruben Adler Research Award from the Wilmer Eye Institute at Johns Hopkins University School of Medicine in 2012, and she was selected as an Emerging Vision Scientist to participate in the Third Annual EVS day on Capitol Hill by the National Alliance for Eye and Vision Research in 2017. In our interview, Natalia tells us more about her life and science.

You tilt your head for one quick scroll — and suddenly your neck, jaw, and temples feel heavier. It's not just “bad posture.” It's a full-body stress signal your brain can't ignore.In this episode of Migraine Heroes Podcast, host Diane Ducarme explores how screens reshape the way your body holds itself — and how those tiny shifts in posture can quietly fuel tension, dizziness, and migraine attacks.Blending neuroscience with Eastern medicine, we break down why the modern digital world is pulling your body out of alignment and your brain into overload.You'll discover:

In this episode, we're joined by Dr. Alan Marmorstein, Professor of Ophthalmology and Director of the Ophthalmic Regenerative Medicine program at Mayo Clinic. For more than three decades, Dr. Marmorstein has led pioneering work in inherited retinal diseases, age-related degeneration, and emerging gene and cell therapies. Tune in to hear about his innovative approach to translating bench science along with insights on mentorship and collaboration  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

In this episode, Dr. Bruno Fernandes acts as host alongside special guest co-host Dr. Carlos Quezada-Ruiz to welcome Dr. Rishi Singh, the newly appointed Chair of Ophthalmology at Harvard Medical School and Mass Eye and Ear, and Chair of the Integrated Department of Ophthalmology at Mass General Brigham. Dr. Singh joins the podcast just 42 days into his new tenure to discuss the transition from the Cleveland Clinic to one of the world's most prestigious academic institutions. Key topics in this episode include: The "First 90 Days" Approach: Why listening is more important than prescribing solutions when taking on a new leadership role. The Circuitous Career Path: How taking on "unsexy" jobs like coding and documentation can build the essential skills needed for executive leadership. AI Realism: Dr. Singh shares his cautious optimism regarding Artificial Intelligence, discussing why it won't solve basic logistical issues instantly and the dangers of relying on the "black box" without human oversight. Retina & Drug Development: A look at the logistical burdens of Wet AMD treatment, the complexities of clinical trials, and the potential (and current limitations) of gene therapy as a "Holy Grail." Mentorship: Why being "uncomfortable" is the best way to grow as a young ophthalmologist. About the Guest: Dr. Rishi Singh is a vitreoretinal surgeon and physician-scientist with over 300 peer-reviewed publications. He formerly served as Vice President and Chief Medical Officer at Cleveland Clinic Martin Hospitals.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Edward Kondrot, MD, an ophthalmologic surgeon who also practices homeopathic medicine. He completed a traditional ophthalmologic residency in 1981 and is also a Doctor of Homeopathic Therapeutics (DHt). Dr. Kondrot also regularly performs medical mission work in Africa. He's also worked locum tenens performing ophthalmologic disability evaluations in veterans. Dr. Kondrot is the author of five best-selling books on eye disease and has an active Substack question and answer program. He sees many patients who have not found an effective treatment with conventional medicine and turn to him for alternatives and hope. His interest in homeopathy was kindled when it offered him a cure for his adult-onset asthma, which had not responded to conventional therapy. During our 20-minute conversation, Dr. Kondrot shared the joy he experiences from helping patients preserve or regain their sight. He is a strong proponent of a healthy and nutritious diet to optimize physical function and promote healthy aging. Dr. Kondrot can be reached at his website: healingtheeye.comOr by email: drkondrot@healththeeye.com (For those interested in ophthalmology, please check out Episode #124 with Dr. Daniel Laby, sports vision Specialist.)  #eye #eyedisease #ophthalmology #medicalmission #homeopathy #locumtenens #locumsPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. Follow me on Instagram: @andrewwilnermd X: @drwilner linkedin.com/in/drwilner Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com This production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwil...

Send me a question or story!Periocular dermatitis can occur for a multitude of reasons. The first step is to figure out if the eye itself is involved or not. Once we know the eye is healthy, it is time to figure out why the SKIN AROUND the eye is losing hair, crusty, itchy, etc.It is important to return to the basic diagnostics. Cytology can be sampled with tape (if the lesion is dry) or swab (if the lesion is wet) to not risk damaging the eye. A trichogram can be used instead of a skin scrape to also protect the eye from a scalpel blade!Anything that can cause folliculitis to other areas of the skin can impact the periocular dermatitis. Allergies, mites, dermatophytosis, pyoderma, yeast dermatitis, autoimmune diseases and neoplasia can cause lesions. Dive into the details on this week's episode of The Derm Vet podcast!Timestamps00:00 Intro03:00 Periocular Dermatitis05:21 Cytology Techniques06:45 Allergies and Facial Pruritus08:20 Demodex12:00 Biopsy13:20 Neoplasia16:00 Outro

Want to Start or Grow a Successful Business? Schedule a FREE 13-Point Assessment with Clay Clark Today At: www.ThrivetimeShow.com   Join Clay Clark's Thrivetime Show Business Workshop!!! Learn Branding, Marketing, SEO, Sales, Workflow Design, Accounting & More. **Request Tickets & See Testimonials At: www.ThrivetimeShow.com  **Request Tickets Via Text At (918) 851-0102   See the Thousands of Success Stories and Millionaires That Clay Clark Has Helped to Produce HERE: https://www.thrivetimeshow.com/testimonials/ Download A Millionaire's Guide to Become Sustainably Rich: A Step-by-Step Guide to Become a Successful Money-Generating and Time-Freedom Creating Business HERE: www.ThrivetimeShow.com/Millionaire   See Thousands of Case Studies Today HERE: www.thrivetimeshow.com/does-it-work/  

What is a call? How does a person know if God is calling them to mission service? Join in a discussion as these and other questions are addressed.

Send us a textAbout Dr. Michael Lipson:Dr. Michael Lipson is recently retired from his position as an optometrist/associateprofessor at University of Michigan, department of Ophthalmology and Visual Science.His clinical practice involves specialty contact lenses: OrthoK, keratoconus, post-corneal transplant, post-refractive surgery and severe dry eye patients. He has published peer-reviewed clinical research studies on OrthoK, vision-related quality of life, myopia management and new lens designs. He lectures nationally and internationally on those same topics. Dr. Lipson developed a validated questionnaire to assess vision-relatedquality of life for all types of vision correction, including OrthoK. He has authoredchapters in textbooks on OrthoK, scleral lenses and general contact lens topics. Dr.Lipson is the author of the book “Contemporary OrthoKeratology”. He also is a reviewerfor a number of highly-respected peer-reviewed journals in the ophthalmic community.He is a consultant to the specialty contact lens industry emphasizing OrthoK education.He is on the GPLI Advisory Board, served as Vice-President of the Scleral Lens EducationSociety and served on the Scleral Lens Education Society Board for many years.---If you're considering or have ever considered getting a virtual team member for your practice check out hiredteem.com, mention The Myopia Podcast when signing up for a $250 dollar discount off of your first month's teem member.https://hireteem.com/myopia-podcast/

In this episode, we sit down with Dr. Jean Bennett, Professor Emeritus of Ophthalmology at Penn Medicine and a true pioneer in gene therapy research. Dr. Bennett led the team that developed the first FDA-approved gene therapy to treat inherited blindness, transforming the lives of patients with retinitis pigmentosa and other retinal diseases. Her groundbreaking work spans over three decades and has opened doors for gene therapy applications far beyond ophthalmology. Dr. Bennett shares her remarkable journey from a curious child in New Haven, Connecticut—who chose seeds over candy at age four—to becoming a world-renowned scientist. She opens up about the challenges she faced as a woman in science, including being advised to leave her field entirely when seeking tenure at Penn. With candor and humor, she discusses how mentorship from previous Girl Power Gurus guest, Dr. Virginia Lee, helped her persevere, the emotional eureka moment when blind dogs first regained their sight, and what it felt like to witness blind children see for the first time. Dr. Bennett also offers invaluable advice for young women pursuing STEM careers, emphasizing the importance of finding work you love, building collaborative teams, and never giving up on your dreams despite the obstacles. This is a must-listen for anyone interested in science, medicine, or the power of determination.

Theresa Heah, M.D., MBA, co-founder, vice-chair, and CEO of Eyexora, speaks with host Carey Powers at this year's Ophthalmology Innovation Summit about her company's fresh approach to building an ophthalmology company that centralizes R&D, clinical, regulatory, and commercial expertise into a “one-stop shop.” Heah delves into the advantages of the hub and spoke model and how it will help overcome the gaps in the eye care landscape, as well as their plans to expand to the UK. In this episode of the OIS podcast, learn about:  · Eyexora's mission as a unique hub and spoke company dedicated to accelerating clinical innovation ·  The barriers in the ophthalmology field and how Eyexora's approach will help overcome them ·  The advantages of building relationships on a global scale ·  Milestones and scientific areas to look out for in 2026 RESOURCES:  Carey Powers: https://ois.net/carey-powers/  Theresa Heah: https://www.linkedin.com/in/theresaheah  Eyexora: https://eyexora.com/ 

"It's recommended that everyone over the age of 40 go see their eye doctor once a year." -Dr. Rudrani Banik   Dr. Rudrani "Rani" Banik is a renowned board-certified neuro-ophthalmologist and an integrative medicine specialist based in New York City. She holds the position of Associate Professor of Ophthalmology at Mount Sinai and has an impressive educational background, including an MD from Brown University, a residency at UC Irvine, and a fellowship at the Wilmer Eye Institute at Johns Hopkins. Dr. Banik adopts a holistic approach to eye health, focusing on nutrition, lifestyle, and supplementation. She is also a prolific author and media expert, featured on platforms like Good Morning America, NBC, and The New York Times. Episode Summary: Join host Jana Short in an engaging conversation with Dr. Rudrani "Rani" Banik, renowned neuro-ophthalmologist and integrative medicine specialist, as they delve into the intricacies of eye health and holistic wellness. In this enlightening episode, Dr. Banik shares her personal journey with chronic daily migraines, which led her to discover the powerful potential of lifestyle and dietary changes in managing health conditions. With a foundation in conventional medicine, she transitioned to a more integrative approach, emphasizing the importance of diet, stress management, and functional medicine in overall well-being.   Throughout the episode, Dr. Banik discusses her innovative work in eye health, emphasizing the role of nutrition and supplements in maintaining optimal vision. She elaborates on the extensive array of nutrients, beyond the well-known carrots, that contribute to eye health, such as lutein and zeaxanthin. Her insights extend to the necessity of regular eye examinations and lifestyle adjustments to protect and preserve ocular health. Dr. Banik also introduces her supplement line, Ageless by Dr. Rani, and her book, "Beyond Carrots," showcasing her dedication to educating others on the significance of holistic eye care.   Key Takeaways: Dr. Rani Banik's journey with chronic migraines led her to embrace integrative medicine, highlighting the impact of diet and lifestyle on health management. Regular eye checkups are crucial, as the eyes can reveal early signs of over 200 medical conditions. Beyond carrots, nutrients like lutein, zeaxanthin, and meso-zeaxanthin are vital for eye health, acting as internal sunglasses and blue blockers. Incorporating diverse foods, such as leafy greens, bell peppers, and spices, can significantly reduce the risk of eye diseases. Supplements should complement a healthy diet, filling in nutritional gaps due to factors like dietary absorption or soil nutrient depletion.   Resources: www.drranibanik.com https://www.facebook.com/rudrani.banik.2025/ @‌dr.ranibanik https://x.com/RudraniBanikMD     ✨ Enjoying the show? Stay inspired long after the episode ends! Jana is gifting you **free subscriptions to Ageless Living Magazine and **Best Holistic Life Magazine—two of the fastest-growing publications dedicated to holistic health, personal growth, and living your most vibrant life. Inside, you'll find powerful stories, expert insights, and practical tools to help you thrive—mind, body, and soul.  

We tend to think of eyesight as a technical problem—retinas, optics, refractive errors, clearer lenses. But eyes don't just see—they interpret. They blur when the world feels too intrusive, or sharpen when clarity feels like safety. The eyes are woven through with story, memory, emotion, and the ways we've learned to look—or to look away.In this conversation with Dr. Marc Grossman, optometrist, acupuncturist, and lifelong investigator of vision, we explore how eyesight is more than biology—it's biography. He's spent decades asking not just what eye problems are, but why they appear in this person, at this moment, in this way. His work lives at the intersection of physiology, psychology, Chinese medicine, and the soul's need to see clearly—not just out into the world, but into one's own experience and heart.Listen into this discussion as we explore how nearsightedness can emerge from emotional overwhelm, why some people develop tension in just one eye, how the optic nerve can reflect sensitivity and empathy, and why prescriptions sometimes don't correct—but instead freeze—a moment in our story.This isn't a conversation about fixing eyes. It's about recognizing eyesight as a living conversation between body, spirit, and the world we orient ourselves toward. It reminds us that inquiry—not protocol—is often the most powerful medicine.

Senator Rand's governmental website: https://www.paul.senate.gov _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad To subscribe to my exclusive content on X, please visit my bio at https://x.com/GadSaad _______________________________________ This clip was posted on December 8, 2025 on my YouTube channel as THE SAAD TRUTH_1954: https://youtu.be/3TZAi-GqqLM _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense.  _______________________________________

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Retinal Vein Occlusion⁠⁠⁠⁠ from the Ophthalmology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Endophthalmitis⁠⁠⁠⁠ from the Ophthalmology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cataracts from the Ophthalmology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subconjunctival Hemorrhage⁠⁠⁠⁠ from the Ophthalmology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Contributor: Megan Hurley, MD Educational Pearls: Assess first: confirm the hook isn't near vital structures. Automatic subspecialty consult for eye involvement or proximity to carotid artery, radial artery, peritoneum, testicle, or urethra Barbed hook: cannot be pulled back through the entry without disengaging the barb Removal Techniques String-Pull: best for superficial, single-barbed hooks Depress shank and eye of hook to disengage barb and then pull string taut and jerk suddenly along the long axis Can only be used when the hook is in a body part that can be firmly secured so it won't move during the procedure Little or no anesthesia needed Push-Through & Snip: best choice when barb is near the skin surface Anesthetize first and advance the hook forward until the barb emerges. Cut off the barb and then back hook out Small exit wound, no sutures needed Needle Cover: for larger hooks that are superficial Anesthetize first and then slide an 18 or 20-gauge needle along the hook until the bevel covers the barb. Then back out the needle and hook together Cut-it-out: last resort Make an incision along the body of hook to barb and then remove hook Adjuncts: Hydrodissection with lidocaine along the tract can ease removal Post-Procedure Irrigate thoroughly and apply antibiotic ointment Routine prophylaxis not needed because complications are rare Consider prophylactic antibiotics if hook is deeply embedded in high-risk area or contaminated by fresh water or salt water References Aiello LP, Iwamoto M, Guyer DR. Penetrating ocular fish-hook injuries. Surgical management and long-term visual outcome. Ophthalmology. 1992 Jun;99(6):862-6. doi: 10.1016/s0161-6420(92)31881-0. PMID: 1630774. Malitz DI. Fish-hook injuries. Ophthalmology. 1993 Jan;100(1):3-4. doi: 10.1016/s0161-6420(93)31700-8. PMID: 8433823. Summarized by Meg Joyce, MS2 | Edited by Meg Joyce & Jorge Chalit, OMS4